The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular ...

Parkinson's disease (PD) is a neurodegenerative disorder in which the α-synuclein protein abnormally aggregates within brain cells, causing neuronal damage. Through international collaboration, ...

A collaborative study by scientists at the University of California, Riverside, and University of Southern California reports on how a process known as alternative splicing, often described as ...

Emerging research suggests reversible RNA editing mechanisms may influence heart disease biology while opening new avenues for biomarkers and next-generation cardiovascular therapies. Review: RNA ...

RNA-based therapeutics use RNA as a blueprint that enables cells to produce specific proteins—including proteins that can ...

Wave Life Sciences (WVE) was not the only developer of RNA editing therapies to show significant stock gains from its historic proof-of-mechanism for its RNA editing platform, shown recently in the ...

Wave Life Sciences said today its alpha-1 antitrypsin deficiency (AATD) candidate WVE-006 succeeded in the first-ever clinical demonstration of RNA editing in humans by achieving positive ...

A collaborative research study co-led by scientists at the Icahn School of Medicine at Mount Sinai and the Liber Institute for Brain Development has for the first time identified a biological process ...

Pharmaceutical start-up AIRNA has raised $90 million in an oversubscribed series A financing round. The firm aims to produce drugs that edit RNA transcripts in the body. AIRNA obtained an initial $30 ...

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PRQR) (ProQR), a clinical-stage company ...